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1. Introduction 
Liver biopsy is still the most accurate tool to assess liver histopathology in chronic liver disease 
(CLD), especially in patients with chronic active hepatitis who need a treatment decision. 
Nowadays, there are many non-invasive methods are being used to assess liver fibrosis and 
might replace liver biopsy. One of the new methods is transient elastography (TE/Fibroscan) 
which has been widely used to predict liver fibrosis in chronic active hepatitis B and C. 
However, whether TE is ready to replace the liver biopsy is still controversial.  
In cases like chronic hepatitis B infection (CHB), autoimmune hepatitis (AIH), non-alcoholic 
steatohepatitis (NASH), drug induced liver injury (DILI), and cholestatic liver diseases, the 
role of liver biopsy is very important to make the whole information of liver histopathology 
(not only about liver fibrosis). On the other hand, to make a diagnosis of liver cirrhosis, we 
have some parameters that can be used, such as clinical stigmata of advanced chronic liver 
disease (jaundice, hyper pigmentation, spider nevi, palmar erythema, ascites, edema, and 
others), low level of platelet count, and low level of albumin, prolonged protombin time, 
and picture of liver cirrhosis based on ultrasound examination.  
In chronic active hepatitis B infection, the treatment decision is usually based on the increase 
level of alanine aminotransferase (ALT), high HBV-DNA serum level, and the presence of 
HBeAg status. In patients with normal ALT level or less than 2x ULN, the liver biopsy is 
needed to decide whether the antiviral therapy should be started or not. In this group, not 
only liver fibrosis assessment is important, but also the degree of necroinflammation will 
influence the decision of antiviral therapy. From the point of view of liver fibrosis itself 
when using TE, it is not always accurate to differentiate between fibrosis 1 or 2, since this 
differentiation is also important to start antiviral therapy.  
Despite the etiology of liver injury, TE itself has problem with overweight and obese patients, 
and patients with narrowed intercostals space. TE also cannot be performed in ascitic patient 
because the interposed fluid blocks the shear wave. The increase of liver stiffness cut off is also 
can be influenced by metabolic syndrome, age, BMI, and the increase of ALT level. 
The liver biopsy still has the most important role in assessing liver histopathology but we 
might reduce the need of liver biopsy examination in some patients. At this moment, TE can 
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be used as a predictor tool in assessing liver fibrosis in chronic active hepatitis with regard 
to clinical and laboratory parameters.  
A lot of study is still needed to validate the usefulness of TE in assessing liver fibrosis in 
chronic active hepatitis.  
2. Liver biopsy 
2.1 History and definition 
In 1883, the first liver biopsy was performed by Ehrlich to assess hepatic glycogen content in 
a diabetic patient, followed by Lucatello who performed liver biopsy to analyze a tropical 
abscess of the liver 12 years later. In 1907, Schuper is the one who published a series number 
of liver biopsy which are performed in humans and rats. The liver biopsy technique has 
been evolved for many years, and in 1958 Menghini technique of liver biopsy has been 
introduced and widely used in the clinical practice. This technique can be easily performed 
by experienced and well-trained clinicians and especially hepatologists. Liver biopsy is a 
technique to obtain, view, and assess the liver histology, either by cutting or aspiration. This 
technique can be done via transcutaneous route, or transjugular. (1) 
 
 
Copyright 2006 by Elsevier Inc. 
Fig. 1. Typical set-up of materials required for an aspiration transcutaneous liver biopsy. 
The syringe is already connected to an aspiration needle (Menghini) biopsy set.  
The other syringe is used for local anesthesia. Adapted from Zakim and Boyer’s 
Hepatology 2006. 
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Fig. 2. The approach to transcutaneous liver biopsy. A transcutaneous biopsy of the liver is 
performed in complete expiration to limit accidental pulmonary injury. As the liver is 
frequently cirrhotic and therefore small, an intercostal approach is necessary. However, in large 
livers a subcostal route is preferred as a safer route. The schematic illustrates the two principal 
types of needle used: cutting needles and aspiration needles, for which several models are 
commercially available and which should be chosen according to the patient's risk profile and 
the clinical indication for the biopsy. Adapted from Zakim and Boyer’s Hepatology 2006. 
2.2 The clinical importance of liver biopsy: Its use, risk and assessment 
Liver biopsy is an important examination in assessing the progression of liver disease, 
establish the diagnosis when there is no clear etiology, and to make a decision of therapy. 
We know that the risks of liver disease progression are liver cirrhosis (LC) and liver 
cancer/hepatocellular carcinoma (HCC). These could be due to chronic active hepatitis virus 
infection (such as hepatitis B (HBV) and C (HCV) virus), drug induced liver injury (DILI), 
alcoholic liver disease (ALD), non-alcoholic steatohepatitis (NASH), autoimmune hepatitis 
(AIH), etc. In chronic active hepatitis virus infection, of course we need to do liver biopsy in 
special circumstances (based on the guidelines). However, the disease such as AIH, DILI, 
and NASH, liver biopsy examination could be a mandatory since we need to see clearly the 
histology picture to establish the diagnosis. Even sometimes, patient with unknown etiology 
of hepatomegaly with abnormality liver biochemistry test, we do need a liver biopsy. Liver 
biopsy in Non-Alcoholic Fatty Liver Disease (NAFLD) can become a dilemma since we 
know that not all patients with fatty liver will develop NASH. There were some contrarily 
about doing liver biopsy since there are side effects that could happen, such as 
bleeding/hemorrhage and pain. The frequency of complications was 3.2% in physicians 
with a history of less than 20 biopsies, compared to 1.1% when over 100 had been 
performed. Recently, the use of ultrasound as a guide to liver biopsy has been used widely 
among the hepatologists. Many recommendations has also been made regarding to liver 
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biopsy preparation but there is still lack of evidence. The only thing is that really matters are 
anticoagulant use and hemostase examination.   Sampling error is that something that could 
happened because we only use small needle and probably we could only assess small area 
of the liver tissue even though we have the preconditions for liver tissue sampling so it can 
be assessed very well by the pathologist. However, until now liver biopsy is still a gold 
standard to obtain information about what happened in the progression of liver diseases 
and of course to see the improvement of liver histology after the patients received treatment. 
In Advanced liver disease, we have clinical (chronic liver disease stigmata such as icteric, 
spider nevi, hyper pigmentation, palmar erythema, splenomegaly, ascites, caput Medusa, 
and leg edema), biochemical parameters (low platelet count, albumin globulin ratio, 
hyperbilirubinemia, abnormal hemostase, etc), and imaging studies (ultrasound, CT-scan, 
MRI) to confirm the diagnosis so we don’t have to perform any liver biopsy. (2,3,4,5) 
 
  
Fig. 3. Liver Cirrhosis and Hepatocellular Carcinoma Illustrations. 
2.3 Non invasive methods in assessing liver fibrosis 
The ideal non invasive methods in assessing liver fibrosis should be highly sensitive and 
specific, technically easy to measure, inexpensive, minimal or no side effect, and can be 
used easily to monitor the progression or regression of liver disease during the treatment. 
There are several direct and indirect serum markers that have been studied for long time 
to assess liver fibrosis. The direct markers such as collagens (procollagen I C 
peptide/PICP, procollagen III N peptide/PIIINP, type IV collagen and its fragments (NC1 
and PIVNP), glycoproteins and polysaccharides (hyaluronic acid/HA, laminin, tenascin, 
YKL-40/chondrex), collagenase and their inhibitors (metalloproteinases/MMPs, tissue 
inhibitors of metalloproteinases/TIMPs), and cytokines (TGF-┚1 and PDGF) are related to 
matrix deposition since we know that the activation process of stellate cell which is the 
key event of liver fibrosis is related to the increase production of MMP-1, MMP-2, and 
TIMPs, and leading to replacement by interstitial collagen. However, most of the studies 
showed the significant difference between no or mild fibrosis group (F0-F1) and 
moderate-severe liver fibrosis group (F2-F4) or between F0-F2 vs. F3-F4 group. (6,7,8,9,10) 
When it comes to differentiate between F1 and F2, most of the studies showed unsatisfied 
result. Mostly have not very high sensitivity when it is used to differentiate between F1 
and F2. In a large cohort study, nine different markers have been evaluated in HCV, ALD, 
and NAFLD patients, and it is found that HA, TIMP-1, and PIIINP were selected as 
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having the best accuracy in diagnosing F2-F4 with the AUROC were 0.77, 0.94, and 0.87. 
Another large study in 696 HCV patients has shown that HA, TIMP-1 and ┙-2-
macroglobulin were having 75% accuracy in diagnosing F2-F4 with AUROC 0.82-0.83. 
Zhang BB et al also showed very good results of the direct serum markers such as PDGF-
BB, TIMP-1, TIMP-1/MMP-1, and TIMP-1mRNA when diagnosing hepatic inflammation 
and fibrosis in CHB patients compared to normal control. It showed good correlations  
(r=0.239-0.565; p=0.000-0.0033), but in this study didn’t show any differences between 
fibrosis stages. Study by Oberti et al, showed that the best diagnostic accuracy was found 
for HA, laminin, PIIINP, and TGF-┚1, but it didn’t show any diagnostic advantage when 
those markers were taken together. All of these markers are not liver specific as it might 
be influenced by some other conditions, such as inflammation at any other organs. The 
value of these markers in diagnosing the liver condition also can be questionable whether 
due to the progression of matrix deposition or recovery process after inflammation 
process. (6,11,12) The cost-effectiveness of the non-invasive markers is still debatable since 
in most countries in Asia, the price of non-invasive markers can become a problem when 
it comes to the market.  
The indirect markers such as serum ALT levels, AST/ALT ratio, platelet count (PT), 
prothrombin index, and multi-combination indirect fibrosis test (Forns index, Fibro Test, 
APRI, PGA, PGAA, FIB-4, Hepascore and Acti Test) also have been studied for many years 
whether it could be used to replace liver biopsy or not. The simple indirect marker test such 
as ALT level seemed that is not really a good marker in hepatic fibrosis prediction since 
there have been many studies showed that even though patients with normal ALT could 
possibly have advance liver fibrosis. (8,13,14,15,16) The AST/ALT ratio showed a good 
predictive value in advanced liver disease, especially when combined with platelet count 
which has been reported mostly in CHC patients. A retrospective study by Yilmaz et al 
showed statistically significance for the correlation between APRI score and hepatic 
fibrosis in CHC (r=0.2634, p=0.0059) and NAFLD (r=0.2273, p=0.0069) patients but not in 
CHB (r=0.1005, p=0.1495) patients even though the r values showed not very strong 
correlation. This study also found that APRI has sensitivity 55.0% and specificity 75.4% 
for CHC, 60.0% and 73.3% for NAFLD, and 55% and 75.4% for CHB. (17) Another 
retrospective study comparing 6 non-invasive liver fibrosis markers (APRI, Fibrometer, 
FIB-4, Hepascore, Forns index, and Shanghai Liver Fibrosis Group/SLFG’s index) showed 
that better correlation were found in Fibrometer (r=0.69), Hepascore (r=0.62), and SLFG 
(r=0.68) with METAVIR score (p< 0.001) of liver histopathology compared with others. 
Fibrometer, Hepascore, and SLFG are more representing direct markers while APRI, FIB-
4, and Forns index are indirect markers. However, in this study only showed the AUROCs 
were better when these markers are used to differentiate between F0-F2 and F3-4 
compared to F0-1 and F2-4 group. (18) 
2.4 Imaging studies in assessing liver fibrosis 
There are some imaging studies that can be used to assess the liver morphology such as 
ultrasound, CT-scan, and Magnetic Resonance Imaging (MRI). However, none of these 
modalities can be used when the differentiation between mild and early significant liver 
fibrosis is needed. In chronic active hepatitis, the only finding that can be found with these 
imaging modalities is the cirrhotic liver. (7,19) On the other side the imaging studies like CT-
scan and MRI will cost a lot of money. A retrospective cross sectional study looking at 
comparative MR imaging studies with superparamagnetic iron oxide (SPIO)-enhanced and 
www.intechopen.com
 
 Liver Biopsy 
 
8 
double-enhanced spoiled gradient echo (SPGR) sequences in 101 patients (HCV, HBV, AIH, 
NASH, PBC, PSC, alcoholic hepatitis, and cryptogenic) showed that qualitative and 
quantitative image scores were significantly higher for patients with METAVIR fibrosis 
scores of 3 or higher than for those with scores of 2 or lower (p < .001). Diagnostic 
performance for detection of grade 3 or more severe fibrosis was better with the doubled-
enhanced sequence than with the SPIO-enhanced sequences. This study showed a good 
performance only when it comes to assess advanced liver fibrosis. The limitations of this 
study were retrospective study and only have a small number patient with mild fibrosis.(20) 
During the development of imaging studies, a modified phase contrast magnetic resonance 
(MR) imaging sequence to assess liver tissue shear waves, which is called MR elastography, 
also has been studied. In twelve patients with chronic liver disease (HCV, AIH, NASH, liver 
cirrhosis due to sarcoidosis) who underwent MR elastography, there were 11 patients with 
liver fibrosis (stage 1 in four patients, stage 2 in three patients, stage 3 in three patients, and 
stage 4 in one patient) based on histopathology results and from the imaging result showed 
that the mean liver stiffness was significantly higher than was found in healthy control 
group (p < .001). This preliminary study has shown that MR elastography can be used to 
differentiate between normal and fibrotic liver but still it needs a lot of sample to confirm 
these findings especially when it will be used to differentiate between mild and advance 
liver fibrosis. (21) 
2.5 Transient elastography (Fibroscan) in assessing liver fibrosis 
Transient Elastography (TE/Fibroscan, Echosens, Paris, France) has been introduced recently 
as a new tool for liver fibrosis assessment. It is an easy and user friendly technique for 
clinicians and very comfortable examination for the patients. The non-fasting patients lying 
flat on their back, with the right arm tucked behind the head to facilitate access to the right 
upper quadrant. The ultrasound transducer probe is mounted on the axis of a vibrator and the 
elastic shear wave induced by the vibrations will propagates through the liver tissue. The 
examination will takes only less than 5 minutes in experienced and well trained clinicians or 
nurses (after 100 examinations).  Liver stiffness values range from 2.5 to 7.5 kPa. The validity of 
this examination depends on the interquartile range (IQR), which reflects the variability of the 
validated measures, and should not exceed 30% of the median value. The success rate should 
be at least 60%. The limitations of this examination are when dealing with obese patients, 
patients with ascites, and high ALT level. Failure rates to perform this examination in high 
BMI patients have been showed in several studies and the range was showed between 2.4% 
and 9.4%. (22,23) The level of ALT has become a major issue since many studies have shown 
that higher ALT will make the higher liver stiffness value. (24,25,26) Most of the TE studies in 
Western countries were done in CHC patients since we know that CHC is more prevalent. On 
the other side, most Asian countries tried to look this new tool for liver fibrosis assessment in 
CHB patients. There are several major issues when we look two sides of the world’s 
perspective about this examination. First, the different etiology of the liver disease could make 
the difference of liver stiffness value even though there were some studies in CHB patients 
done in Western countries and showed the similar proposed cut off with CHC for F2. In Asian 
countries, many factors have been known can influence the progression of liver disease such as 
metabolic factors, medicines, genetic polymorphism, and viral genotype. These factors could 
contribute differently when compare to Western countries. Second, the liver stiffness value 
impact between CHC and CHB is still debatable in liver fibrosis measurement. When 
diagnosing the liver fibrosis progression to consider for antiviral therapy, in CHC patients 
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probably is simpler than in CHB patients because in CHB not only the fibrosis is important but 
also the necroinflammation of the liver. Third, the AUROCs for F2 prediction in CHB which 
were reported in Asian studies found lower value than it found in Western studies. Beyond 
this point, study by Chan et al has showed there was a grey area  in CHB patients with normal 
ALT between LSM 6.0-9.0 kPa, where a LSM 5.0-6.0 kPa would indicate insignificant fibrosis, a 
LSM >9.0 kPa had a high chance of bridging fibrosis, and that >12.0 kPa had a high chance of 
cirrhosis. It means in this grey zone the liver biopsy might be needed. (24,27,28) The use of TE 
in liver cirrhosis (LC) patients is still controversies since we have a lot of non-invasive 
parameters that can be used to diagnose LC. In some special conditions such as hemophilia, 
aplastic anemia, thrombocytopenia not related to liver disease, etc, TE might be a good 
consideration when those patients suffered from chronic active hepatitis virus infection  
(B & C).  
 
 
Fig. 4. Fibroscan. 
2.6 Liver biopsy or non invasive method in clinical practice 
In clinical practice, it is not about which one is better to another method in liver fibrosis 
assessment but it is more important to see patient to patient’s problem based. The final 
purpose of all these is to make a better clinical decision for the patient but not for the 
doctor because most patients would like to know whether they have advanced fibrosis or 
not. Overall, we need to give more concern in patient’s safety, cost-effectiveness, and of 
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course what advantage that the patient will have from each examination for disease 
management. 
3. Conclusions 
Liver biopsy still has an important role in the non-invasive methods era even though the 
need of liver biopsy could be reduced with many kinds of non-invasive methods in liver 
fibrosis prediction. Further development of non-invasive methods is still needed since we 
haven’t found the perfect non-invasive method that can entirely replace liver biopsy 
examination.   
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